Guardant Health Company Top Insiders

GH Stock

USD 87.27 -1.48 -1.67%

Under 93 percent of Guardant Health's insiders are actively selling. The analysis of insiders' sentiment of trading Guardant Health stock suggests that a large number of insiders are panicking at this time. Guardant Health employs about 2.5 K people. The company is managed by 16 executives with a total tenure of roughly 18 years, averaging almost 1.0 years of service per executive, having 155.63 employees per reported executive.

Helmy Eltoukhy CEO

CoCEO CoFounder

AmirAli Talasaz President

President COO, Director

Insider Sentiment

Mostly Selling

Selling

Buying

Latest Trades

2026-03-16	Michael Brian Bell	Disposed 3000 @ 87.04	View
2026-03-06	Medina Manuel Hidalgo	Disposed 1300 @ 91.54	View
2026-01-21	Terilyn J Monroe	Disposed 8571 @ 114.09	View
2026-01-07	Terilyn J Monroe	Disposed 10031 @ 112.08	View
2025-12-17	Musa Tariq	Disposed 116 @ 101.46	View
2025-12-15	Helmy Eltoukhy	Disposed 90565 @ 103.82	View
2025-12-08	Amirali Talasaz	Disposed 100000 @ 105.05	View
2025-12-05	Chris Freeman	Disposed 31452 @ 103.07	View
2025-12-01	Terilyn J Monroe	Disposed 55167 @ 105.97	View
2025-11-21	Sheldon Whitehouse	Acquired @ 105.42
2025-11-19	Musa Tariq	Disposed 116 @ 96.25	View
2025-11-07	Medina Manuel Hidalgo	Disposed 1500 @ 95.19	View
2025-10-17	Musa Tariq	Disposed 116 @ 66.95	View

Insider-sentiment monitoring for Guardant Health is useful because insiders may respond to operating developments before those shifts are fully reflected in market commentary. The signal is still regulated and disclosed under securities law, which is why the public filing record matters more than rumor or interpretation alone.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment in Guardant Health is commonly read through disclosed transactions filed by individuals who may have a closer view of operating direction than outside investors. Used properly, insider trading data is contextual rather than absolute because corporate insiders can transact for several reasons that are not purely directional.

Build portfolio with Guardant Stock

latest congressional trading

Government-trading disclosures involving Guardant Health matter because they give the market another transparency channel for politically exposed investors. Current market capitalization is about 11.68 Billion. These disclosures do not automatically imply an edge, but they do create a public record that investors can monitor.

	2025-12-01	Senator Sheldon Whitehouse	Acquired under $15,000		Verify
	2025-11-30	Senator Sheldon Whitehouse	Acquired under $15,000		Verify

Management Team Effectiveness

The company has Return on Asset (ROA) of -15.59 % which means that on every $100 spent on assets, it lost $15.59. This is very low relative to industry peers. Likewise, it shows a return on total equity (ROE) of -4584.47 %, which implies that shareholder value decreased during the period.

As of today, Common Stock Shares Outstanding is anticipated to decline to approximately 101.3 M. In addition to that, Analyst projections suggest Net Loss may climb to approximately -559.7 M.

Stock Institutional Investors

About 95.98% of Guardant Health is held by institutions, with insiders at 4.02%. Current market capitalization is about 11.68 Billion. This helps separate index flows from active bets. Shares outstanding are near 131.2 M. Whether the institutional base is growing or shrinking quarter over quarter matters more than the current snapshot.

		Shares
Fmr Inc	2025-12-31	2.4 M
Two Sigma Advisers, Llc	2025-12-31	2.4 M
Fuller & Thaler Asset Management Inc	2025-09-30	2.4 M
Ubs Asset Mgmt Americas Inc	2025-09-30	2.3 M
Two Sigma Investments Llc	2025-12-31	2.2 M
Driehaus Capital Management Llc	2025-12-31	2.1 M
Lord, Abbett & Co Llc	2025-12-31	2 M
Federated Hermes Inc	2025-09-30	1.8 M
The Goldman Sachs Group Inc	2025-09-30	1.5 M
Vanguard Group Inc	2025-12-31	12.2 M
Blackrock Inc	2025-09-30	11.4 M

For a mid-cap like Guardant Health (11.68 Billion), benchmark pressure and redemption cycles can limit how institutional weight turns into price support. Annual revenue is about 982.02 Million. The Guardant Health mid-cap ownership profile should be weighed against balance-sheet strength and earnings trends before drawing conclusions.

Insider Trading Activities

Insider activity around Guardant Health matters because officers and directors often act on business changes before the market catches up. The goal is to tell routine pay-related sales apart from trades that reflect genuine conviction.

		Michael Bell over a week ago Acquisition by Michael Bell of 26582 shares of Guardant Health subject to Rule 16 b-3
		Mignone Roberto over three weeks ago Disposition of 264 shares by Mignone Roberto of Guardant Health subject to Rule 16 b-3
		Tariq Musa over a month ago Disposition of 250 shares by Tariq Musa of Guardant Health subject to Rule 16 b-3
		Kumud Kalia over a month ago Disposition of 3696 shares by Kumud Kalia of Guardant Health subject to Rule 16 b-3
		Hidalgo Medina Manuel over two months ago Acquisition by Hidalgo Medina Manuel of 232 shares of Guardant Health subject to Rule 16 b-3
		Terilyn Monroe over two months ago Disposition of 17379 shares by Terilyn Monroe of Guardant Health subject to Rule 16 b-3
		Helmy Eltoukhy over two months ago Disposition of 23997 shares by Helmy Eltoukhy of Guardant Health subject to Rule 16 b-3
		Kumud Kalia over three months ago Disposition of 2000 shares by Kumud Kalia of Guardant Health at 104.6021 subject to Rule 16 b-3
		Krognes Steve E. over three months ago Disposition of 155 shares by Krognes Steve E. of Guardant Health subject to Rule 16 b-3
		Helmy Eltoukhy over three months ago Disposition of 23997 shares by Helmy Eltoukhy of Guardant Health subject to Rule 16 b-3
		Hidalgo Medina Manuel over six months ago Disposition of 2165 shares by Hidalgo Medina Manuel of Guardant Health at 54.1574 subject to Rule 16 b-3
		Joyce Meghan V. over six months ago Disposition of 100 shares by Joyce Meghan V. of Guardant Health at 65.84 subject to Rule 16 b-3

Outstanding Bonds

Corporate bonds issued by Guardant Health matter because they shape interest expense, maturity risk, and the flexibility management has during tighter credit conditions. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.

	GUARDN 3246 29 MAR 27 Corp Bond US40139LBF94	View
	GUARDN 125 13 MAY 26 Corp Bond US40139LBD47	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	Morgan Stanley 3591 Corp Bond US61744YAK47	View
	Morgan Stanley 3971 Corp Bond US61744YAL20	View
	Valero Energy Partners Corp Bond US91914JAA07	View
	US401378AC83 Corp Bond US401378AC83	View
	US401378AB01 Corp Bond US401378AB01	View

View All Guardant Health Corporate Bonds

Corporate Filings

F4	19th of March 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
F4	18th of March 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
F4	17th of March 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
F4	13th of March 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
F4	9th of March 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
F4	5th of March 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
F4	2nd of March 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
F4	23rd of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify

The majority of Guardant Health's outstanding shares are owned by institutional investors. Large asset managers, pension funds, and sovereign wealth funds that invest on behalf of clients or beneficiaries are typically subject to stricter disclosure rules than retail investors - including mandatory 13F filings that reveal quarterly position changes. Tracking these filings can highlight shifts in institutional conviction around Guardant Health. Guardant Health's share base consists of approximately 96% institutional ownership, 4% insider ownership, and 0% public float.

Shares in Circulation

First Issued

2017-03-31

Previous Quarter

125.3 M

Current Value

128.7 M

Average Shares Outstanding

97.1 M

Quarterly Volatility

26.2 M

Macro event markers

Covid

Interest Hikes

Holders Distribution

Institutional investors in Guardant Health typically operate with more research capacity, technology, and trading scale than retail holders, which is why their activity can materially affect price behavior. Used correctly, the ownership map shows where professional sponsorship may be strong and where exit risk could still be significant.

Workforce Comparison

Guardant Health is rated below average for number of employees among direct rivals. The total workforce of Health Care industry is currently estimated at about 144,710. Guardant Health claims roughly 2,490 in number of employees contributing just under 2% to equities under Health Care sector.

Workforce Revenue Capitalization Total debt Valuation

Compare Guardant Health to Competition

The company has Net Profit Margin (PM) of -42.0 %, which implies that overhead and cost of goods exceed revenue generation. This is very low relative to industry peers. Likewise, it shows Net Operating Margin (NOM) of -43.0 %, which means operating inefficiencies are consuming more than the revenue earned.

Insider Trading History

The buy-sell ratio in Guardant Health's insider history separates pay-related activity from trades based on conviction. Pattern analysis matters more than any single trade. The full record tells the real story.

	Buy/Sell Ratio	# Purchases Trades	# Sales Trades	Total Shares Purchased	Total Shares Sold
2026-03-01	0.7822	79	101	849,372	776,287
2025-12-01	0.437	52	119	563,932	1,216,308
2025-09-01	0.5797	40	69	105,980	535,802
2025-06-01	0.7209	62	86	241,168	465,322
2025-03-01	0.8171	67	82	1,044,091	676,473
2024-12-01	0.8689	53	61	710,820	163,744
2024-09-01	0.6531	32	49	78,742	74,400
2024-06-01	0.8644	51	59	703,754	631,630
2024-03-01	0.7333	33	45	850,106	2,330,359
2023-12-01	1.0294	35	34	354,506	57,934
2023-09-01	0.7143	25	35	283,145	30,269
2023-06-01	1.2105	46	38	353,496	193,749
2023-03-01	1.1579	22	19	211,181	27,279
2022-12-01	1.6667	20	12	324,220	5,845
2022-09-01	1.1667	7	6	172,502	13,218
2022-06-01	0.619	13	21	104,894	290,243
2022-03-01	0.5	4	8	18,110	34,158
2021-12-01	3.2857	23	7	245,325	29,604
2021-09-01	0.9231	12	13	175,417	80,035
2021-06-01	0.2045	18	88	86,086	858,232
2021-03-01	0.0529	9	170	1,149,490	3,775,907
2020-12-01	0.2895	11	38	72,484	7,341,725
2020-09-01	0.225	18	80	351,403	1,322,166
2020-06-01	0.3861	39	101	3,604,883	9,881,143
2020-03-01	0.3684	14	38	108,877	402,992
2019-12-01	0.2857	32	112	344,306	1,029,913
2019-09-01	0.2645	41	155	699,086	6,569,444
2019-06-01	0.2131	26	122	316,133	1,401,323
2019-03-01	2.0	2	1	4,067,980	3,000
2018-12-01	0.717	38	53	62,484,930	89,760,664

Notable Stakeholders

Stakeholders matter for Guardant Health because not every influential participant is a shareholder acting with the same objective or time horizon. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.

Helmy Eltoukhy	CoCEO CoFounder	Profile
AmirAli Talasaz	President COO, Director	Profile
Jennifer Higgins	Senior Affairs	Profile
Stephen Murphy	Senior Marketing	Profile
Gulshan JD	Senior Officer	Profile
John Saia	Chief Secretary	Profile
Christopher Freeman	Chief Oncology	Profile
John JD	Chief Secretary	Profile
Zarak Khurshid	Vice Relations	Profile
Terilyn Monroe	Chief Officer	Profile
Craig MD	Chief Officer	Profile
Andy Ament	Senior Operations	Profile
Kumud Kalia	Chief Officer	Profile
Michael Bell	Chief Officer	Profile
Darya Chudova	VP Technology	Profile
Darl Moreland	Senior Quality	Profile

Management Information & Data Sources

Guardant Health is a large-cap company in Health Care Providers & Services, Health Care Equipment & Services, Health Care. Executive review focuses on insiders, senior management, and employee signals. Governance quality is often reviewed alongside compensation, insider ownership, and reporting discipline. CEO is Helmy Eltoukhy with 2,490 employees and 16 reported executives.

Reported values for Guardant Health are derived from periodic company reporting and market reference feeds and then standardized by Macroaxis analytics. Professional analyst research is incorporated when coverage is available. Refresh times depend on source availability. Insider and management fields are mapped from published filings and company disclosures.

This content is curated and reviewed by:

Rifka Kats - Member of Macroaxis Editorial Board

Last reviewed on March 15th, 2026

Workforce Efficiency and Productivity

Manpower analysis for Guardant Health matters because revenue per employee and profit per employee can reveal shifts in productivity and operating discipline. Used correctly, manpower metrics can highlight whether growth is being supported by better productivity or by heavier staffing costs.

Guardant Health Manpower Efficiency

Return on Guardant Health Manpower

	Revenue Per Employee	394.4K
	Revenue Per Executive	61.4M
	Net Loss Per Employee	167.2K
	Net Loss Per Executive	26M
	Working Capital Per Employee	467.2K
	Working Capital Per Executive	72.7M

Popular Tools for Guardant Stock analysis

	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Global Correlations Find global opportunities by holding instruments from different markets
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.

Macroaxis provides analytical tools and reference data for investors of all levels to evaluate holdings and assess risk across market volatility, economic shifts, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC